Curcumin Conjugates For Treating And Preventing Cancers

Abstract

Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.


Claims
Download PDF
Document Preview
Document History
  • Publication: Apr 21, 2016
  • Application: Dec 21, 2015
    US US 201514977426 A
  • Priority: Dec 21, 2015
    US US 201514977426 A
  • Priority: May 31, 2011
    US US 201113119549 A
  • Priority: Sep 16, 2009
    US US 2009/0057141 W
  • Priority: Dec 9, 2008
    US US 12101908 P
  • Priority: Sep 19, 2008
    US US 9841408 P

Sign in to the Lens

Release 5.10.0: Improved patent search performance, saved query alerts, increased user privacy and more!

Improved Search Performance

Upgraded patent search index servers to improve search performance.

Saved Query Alerts.

Improvements to in saved query alerts emails and better formatting of links.

Increased User Privacy.

Removed Google Maps dependency in a Patents Family page.